Phase I study of oral doxifluridine using two schedules.
Alberto
P
P
Division of Oncology, University Hospital, Geneva, Switzerland.
Winkelmann
J J
JJ
Paschoud
N
N
Peytremann
R
R
Bruyere
A
A
Righetti
A
A
Decoster
G
G
Holdener
E E
EE
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000633:toxicity; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage* / Q000633:toxicity; D006801:Humans; D007536:Isomerism; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D005467:Floxuridine; C025034:doxifluridine